FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says